Your browser doesn't support javascript.
loading
A Novel In Vitro Device to Deliver Induced Electromagnetic Fields to Cell and Tissue Cultures.
Ravin, Rea; Cai, Teddy X; Pursley, Randall H; Garmendia-Cedillos, Marcial; Pohida, Tom; Freidlin, Raisa Z; Wang, Herui; Zhuang, Zhengping; Giles, Amber J; Williamson, Nathan H; Gilbert, Mark R; Basser, Peter J.
Affiliation
  • Ravin R; Celoptics, Inc., Rockville, Maryland; Section on Quantitative Imaging and Tissue Sciences Eunice Kennedy Shriver National Institutes of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.
  • Cai TX; Section on Quantitative Imaging and Tissue Sciences Eunice Kennedy Shriver National Institutes of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland; Wellcome Centre for Integrative Neuroimaging, Nuffield Department of Clinical Neurosciences, University of Oxford,
  • Pursley RH; The Signal Processing and Instrumentation Section, Center for Information Technology, National Institutes of Health, Bethesda, Maryland.
  • Garmendia-Cedillos M; The Signal Processing and Instrumentation Section, Center for Information Technology, National Institutes of Health, Bethesda, Maryland.
  • Pohida T; The Signal Processing and Instrumentation Section, Center for Information Technology, National Institutes of Health, Bethesda, Maryland.
  • Freidlin RZ; The Signal Processing and Instrumentation Section, Center for Information Technology, National Institutes of Health, Bethesda, Maryland.
  • Wang H; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Zhuang Z; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Giles AJ; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Williamson NH; Section on Quantitative Imaging and Tissue Sciences Eunice Kennedy Shriver National Institutes of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland; National Institute of General Medical Sciences, National Institutes of Health, Bethesda, Maryland.
  • Gilbert MR; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Basser PJ; Section on Quantitative Imaging and Tissue Sciences Eunice Kennedy Shriver National Institutes of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland. Electronic address: peter.basser@nih.gov.
Biophys J ; 119(12): 2378-2390, 2020 12 15.
Article in En | MEDLINE | ID: mdl-33189686
ABSTRACT
We have developed a novel, to our knowledge, in vitro instrument that can deliver intermediate-frequency (100-400 kHz), moderate-intensity (up to and exceeding 6.5 V/cm pk-pk) electric fields (EFs) to cell and tissue cultures generated using induced electromagnetic fields (EMFs) in an air-core solenoid coil. A major application of these EFs is as an emerging cancer treatment modality. In vitro studies by Novocure reported that intermediate-frequency (100-300 kHz), low-amplitude (1-3 V/cm) EFs, which they called "tumor-treating fields (TTFields)," had an antimitotic effect on glioblastoma multiforme (GBM) cells. The effect was found to increase with increasing EF amplitude. Despite continued theoretical, preclinical, and clinical study, the mechanism of action remains incompletely understood. All previous in vitro studies of "TTFields" have used attached, capacitively coupled electrodes to deliver alternating EFs to cell and tissue cultures. This contacting delivery method suffers from a poorly characterized EF profile and conductive heating that limits the duration and amplitude of the applied EFs. In contrast, our device delivers EFs with a well-characterized radial profile in a noncontacting manner, eliminating conductive heating and enabling thermally regulated EF delivery. To test and demonstrate our system, we generated continuous, 200-kHz EMF with an EF amplitude profile spanning 0-6.5 V/cm pk-pk and applied them to exemplar human thyroid cell cultures for 72 h. We observed moderate reduction in cell density (<10%) at low EF amplitudes (<4 V/cm) and a greater reduction in cell density of up to 25% at higher amplitudes (4-6.5 V/cm). Our device can be readily extended to other EF frequency and amplitude regimes. Future studies with this device should contribute to the ongoing debate about the efficacy and mechanism(s) of action of "TTFields" by better isolating the effects of EFs and providing access to previously inaccessible EF regimes.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Electric Stimulation Therapy / Glioblastoma Limits: Humans Language: En Year: 2020 Type: Article

Full text: 1 Database: MEDLINE Main subject: Electric Stimulation Therapy / Glioblastoma Limits: Humans Language: En Year: 2020 Type: Article